< Back to previous page
Researcher
Abhishek Garg
- Disciplines:Adaptive immunology, Applied immunology , Innate immunity, Inflammation, Cancer biology, Cancer therapy
Affiliations
- Laboratory of Cell Stress & Immunity (Division)
Responsible
From1 Feb 2020 → Today - Laboratory of Cell Stress & Immunity (Division)
Member
From1 Mar 2020 → Today - Laboratory of Cell Death Research & Therapy (VIB-KU Leuven) (Division)
Member
From30 Oct 2008 → 29 Feb 2020
Projects
1 - 10 of 28
- Towards reverse translational investigation of cancer cell-intrinsic immunotherapy targets in glioblastomaFrom3 Jan 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Unique IsoPlexis technology for multiplexed single cell functional profilingFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Deep multi-omics dissection of the CD8+T-cell immune-landscape in colorectal cancer (CRC) to reveal tumor-specific vs. microbial immune- drivers for immuno-oncological applicationFrom1 Oct 2022 → TodayFunding: FWO senior postdoctoral fellowship
- Building a proprietary platform for DNA-antibody based therapeuticsFrom1 Oct 2022 → TodayFunding: IOF - technology validation in lab
- Next-generation immune biomarkers to improve clinical immunotherapy options for pediatric and adult patients with glioblastoma: a multi-omics, translational immunology and artificial intelligence-driven approachFrom1 Oct 2022 → TodayFunding: Nonprofit institution or equivalents
- Imaging the invisible in preclinical models using magnetic particle imagingFrom1 May 2022 → TodayFunding: FWO Large scale research infrastructure
- Next-generation, multi-technology immune-monitoring and easy-access spectral flow cytometryFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Validating the application of a first-in-class human serum-functional immunodynamic status (sFIS) assay as bona fide immuno-oncology biomarkerFrom1 Oct 2021 → TodayFunding: IOF - technology validation in lab
- Artificial Intelligence/Machine Learning (AI/ML) -driven dissection of the microbiome’s multi-factorial impact on colorectal cancer (CRC) immune-landscape to guide clinical immunotherapy.From1 Oct 2021 → 30 Sep 2022Funding: BOF - postdoctoral mandates
- DIPITO: valorisation of deep immune profiling and novel immunotherapeutics for oncology.From1 Oct 2021 → TodayFunding: IOF - mandates
Publications
1 - 10 of 98
- Regulatory T-cell stability and functional plasticity in health and disease(2023)
Authors: Lidia Yshii, Abhishek Garg, Stephanie Humblet-Baron, Susan Schlenner
Pages: 112 - 129 - CD4+ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment.(2023)
Authors: Abhishek Garg
Pages: 217 - DC vaccines loaded with glioma cells killed by photodynamic therapy induce Th17 anti-tumor immunity and provide a four-gene signature for glioma prognosis(2022)
Authors: Patrizia Agostinis, Abhishek Garg
- The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology(2022)
Authors: Jenny Sprooten, Massimiliano Mazzone, Abhishek Garg
- Immunology of cell death in cancer and infection(2022)
Authors: Abhishek Garg
Pages: 241 - 243 - Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages(2022)
Authors: Isaure Vanmeerbeek, Abhishek Garg, Greetje Vande Velde
Pages: 3785 - 3801 - Severe COVID-19 patients display hyper-activated NK cells and NK cell-platelet aggregates(2022)
Authors: Kourosh Ahmadzadeh, Bram Boeckx, Amber De Visscher, Eline Bernaerts, Pierre Van Mol, Yannick Van Herck, Greet Hermans, Peter Alexander Wilmer, Mieke Gouwy, Abhishek Garg, et al.
- Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma(2022)
Authors: Frederik De Smet, Abhishek Garg, Patrizia Agostinis, Steven De Vleeschouwer
Pages: 1 - 11 - A first-in-class, non-invasive, immunodynamic biomarker approach for precision immuno-oncology.(2022)
Authors: Jenny Sprooten, An Coosemans, Abhishek Garg
- Stress-induced inflammation evoked by immunogenic cell death is blunted by the IRE1 alpha kinase inhibitor KIRA6 through HSP60 targeting(2022)
Authors: Nicole Rufo, Rita Derua, Abhishek Garg, Michael Dewaele, Peter de Witte, Steven Verhelst, Patrizia Agostinis
Pages: 230 - 245